Psoriasis biologic approved for NHS prescribing

Brodalumab (Kyntheum) can now be prescribed routinely on the NHS, after being approved by NICE as a treatment for severe plaque psoriasis.

Psoriasis at any level of severity can be distressing and debilitating, affecting all aspects of life (physical, psychological, social and financial). | iStock
Psoriasis at any level of severity can be distressing and debilitating, affecting all aspects of life (physical, psychological, social and financial). | iStock

Brodalumab is recommended by NICE as an option for treating plaque psoriasis if:

  • the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10, and
  • the disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated.

Approval of brodalumab for NHS use was granted on the condition that the biologic continue to be provided with the discount agreed in the patient access scheme.

NICE states that brodalumab treatment should be stopped at 12 weeks if psoriasis has not responded adequately (defined as a 75% reduction in the PASI score, or a 50% reduction in the PASI score and a 5-point reduction in DLQI from baseline).

'Once this recommendation is implemented, brodalumab, with its differentiated mode of action, will represent a valuable treatment option,' said Professor Richard Warren, Consultant Dermatologist at Salford Royal NHS Foundation Trust and the University of Manchester. 

Mode of action

Brodalumab differs from other biologic therapies for psoriasis as it blocks the activity of pro-inflammatory cytokines involved in plaque formation by specifically targeting the interleukin-17 receptor on skin cells, as opposed to free-floating inflammatory mediators. 

Want news like this straight to your inbox?
Sign up for our bulletins

Sandhiya Sodha recommends

MIMS Dermatology Clinic

Read more

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more